Background
==========

Acute myocardial infarction (AMI) is the most common source of cardiac injuries and greatly contributes to cardiomyocyte ischemic death \[[@b1-medscimonit-22-3562]\]. AMI has emerged as a major health issue worldwide and it results in diminished blood flow to the heart \[[@b2-medscimonit-22-3562],[@b3-medscimonit-22-3562]\]. Major risk factors of AMI include hyperlipidemia, diabetes, smoking, hypertension, sex, and age \[[@b4-medscimonit-22-3562]\]. Furthermore, discovering the molecular mechanisms of AMI may provide additional information for disease management.

MicroRNAs (miRNAs) are a family of conserved, small, non-coding RNAs that regulate target gene expressions \[[@b5-medscimonit-22-3562]\]. Aberrant miRNA expressions have also been documented in many diseases, especially cancer \[[@b6-medscimonit-22-3562]--[@b9-medscimonit-22-3562]\]. Increasing evidence suggests a connection between miRNAs and cardiovascular diseases. Recently, it has been verified that miR-21 is up-regulated in human peripheral blood of patients with atherosclerosis (AS) \[[@b10-medscimonit-22-3562]\]. Therefore, our study specifically aimed to investigate the potential function and regulatory mechanism of miR-21 in acute myocardial infarction.

Phosphatase and tensin homolog (PTEN) encodes a phosphatase with dual activity against phospholipids and proteins \[[@b12-medscimonit-22-3562]\]. PTEN is able to regulate signal transduction pathways through different mechanisms \[[@b13-medscimonit-22-3562]\]. Early research indicated that PTEN is associated with the development of heart failure in mice \[[@b14-medscimonit-22-3562],[@b15-medscimonit-22-3562]\]. Studies revealed that inhibition of PTEN gene expression up-regulated VEGF secretion, increased the migration and proliferation, and stimulated tubule development in pancreatic cancer cells \[[@b16-medscimonit-22-3562]\].

Vascular endothelial growth factor (VEGF) has a substantial impact on endothelial cell proliferation, survival, and differentiation. Hence, VEGF is usually defined as a factor for endothelial-specific growth and angiogenesis \[[@b17-medscimonit-22-3562],[@b18-medscimonit-22-3562]\]. As suggested by another study, VEGF isoforms and subtypes are differently expressed in the infarcted heart \[[@b19-medscimonit-22-3562]\], suggesting the feasibility of detecting VEGF expression after myocardial infarction. Researchers used immunodeficient mice with critical limb ischemia and discovered a miR-21 signal had a negative effect on PTEN, and that VEGF expression was up-regulated \[[@b20-medscimonit-22-3562]\]. All of the above evidence motivated us to carry out this study for the purpose of assessing the relationships among miR-21, PTEN, and VEGF.

Studies on miR-21/PTEN/VEGF are still being developed and few studies have been able to explain how miR-21/PTEN/VEGF affects cardiac microvascular endothelial cells in acute myocardial infarction. Therefore, this study was carried out to assess the effect of miR-21/PTEN/VEGF on angiogenesis in CMEC cells and how miR-21/PTEN/VEGF affects cardiac microvascular endothelial cells.

Material and Methods
====================

Cell extraction and cell culture
--------------------------------

Sprague-Dawley rats (SD rats, Laboratory Animal Center of Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science) with an average age of 2--3 months and weight of 225--350 g were obtained for establishing acute myocardial infarction (AMI) models. Bone marrow mesenchymal stem cells (BMSCs) and cardiac microvascular endothelial cells (CMECs) were isolated from these rats. All experiments were guided by the Care and Use of Laboratory Animals and all experimental procedures were approved by the National Cancer Institute Animal Care and Use Committee.

BMSCs and CMECs of rats were isolated as previously described \[[@b21-medscimonit-22-3562],[@b22-medscimonit-22-3562]\]. All cells were cultured in Dulbecco modified Eagle's medium (DMEM, Gibco, Carlsbad, CA) with 10% fetal bovine serum (Gibco, Carlsbad, CA) at 37°C in an incubator with 5% CO~2~. BMSCs and CMECs were identified by immunofluorescence.

Lenti-virus transduction
------------------------

Four groups of fragments, separately containing miR-21 mimics, miR-21 inhibitors, lenti-PTEN, or VEGF siRNA were cloned into pCDH vectors. Then, pCDH vectors were transfected with other essential packaging plasmids into cells using Lipofectamine LTX kit (Invitrogen, CA) and viral particles therein were collected at 48 h after transfection.

BMSC transfection
-----------------

BMSCs were infected with 3 kinds of recombinant lentivirus and 8 μg/ml polybrene, and then randomly allocated into 4 groups with different transfection substances: control group (BMSCs without transfection); NC group (BMSCs were transfected with control vector); miR-21 mimics group (BMSCs were transfected with miR-21 mimics); and miR-21 inhibitors group (BMSCs were transfected with miR-21 inhibitors).

Establishment of Animal model
-----------------------------

Fifty SD rats were randomly assigned into the control group (n=10) and model group (n=40). An AMI model was established by ligating the left anterior descending coronary artery (LAD) of rats, while rats in the control group were treated with a sham operation \[[@b23-medscimonit-22-3562]\].

As shown in [Figure 1](#f1-medscimonit-22-3562){ref-type="fig"}, all rats were further allocated into 5 groups once the animal model had been established for 2 weeks: control group (10 rats with sham operation, injected PBS into the infarct region); model group (10 model rats, injected with PBS into the infarct region); BMSC group (10 model rats, injected with normal BMSC cells into the infarct region); miR-21 mimics group (10 model rats, injected with BMSC cells which were transfected with miR-21 mimics into the infarct region); and miR-21 inhibitors group (10 model rats, injected with BMSC cells transfected with miR-21 inhibitors into the infarct region). Inspection for all rats was carried out 6 weeks after the operation.

Echocardiographic measurement and tests of endothelial injury markers
---------------------------------------------------------------------

Once the operation had been established for 6 weeks, rats in each group were examined with echocardiographic measurement (ATL-HDI5000, 15MHz linear and 12-MHz sectorial scanheads). Four indexes were inspected for left ventricular ejection fractions (LVEF), fractional shortening (FS), left ventricular end-systolic volume (LVVs), and left ventricular end-diastolic volume (LVVd).

Endothelial injury markers in blood samples including cardiac troponin I (cTnI), heart-type fatty acid binding protein (H-FABP) and von Willebrand factor (vWF) were tested using double antibody sandwich enzyme-linked immunosorbent assay (R&D, USA).

Masson staining and measurement of infarct size
-----------------------------------------------

Six weeks after the operation, rats in each group were sacrificed by injecting xylazine hydrochloride. Sections from base, mid-LV, and apex were harvested and treated with 4% paraformaldehyde. Sections 5-μm thick were embedded with paraffin and then stained by Masson's trichrome assay. Samples were observed under a microscope and infarct size was measured using Image J software (Olympus) at 5 random sites.

Virus transfection in CMECs
---------------------------

CMEC cells were divided into 6 groups: control group (cells without transfection); NC group (cells were transfected with vector); miR-21 mimics group (cells were transfected with miR-21 mimics); miR-21 inhibitors group (cells were transfected with miR-21 inhibitors); miR-21 mimics + lenti-PTEN group (cells were transfected with both miR-21 mimics and lenti-PTEN); and miR-21 mimics + VEGF siRNA group (cells were transfected with both miR-21 mimics and VEGF siRNA).

Cell proliferation and apoptosis assay
--------------------------------------

MTT \[3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide\] assay was used to assess cell proliferation status. Cells (3×10^3^) were cultured in 96-well plates, incubated for 48 h, and then stained with 0.5 mg/ml MTT for 4 h. Supernatant was discarded and 200-μl dimethylsulfoxide was added to dissolve precipitate. Samples were measured at 490 nm using an ELISA reader.

Apoptosis rates of samples were calculated using flow cytometry after cells were stained using the Annexin V-FITC/PI Apoptosis Detection Kit (BD Biosciences).

Tube formation assay *in vitro*
-------------------------------

Tube formation *in vitro* was implemented using a tube formation assay kit (Chemicon). CMEC cells were cultured in 48-well plates with 150 μl matrigel for 6--12 h. Capillary-like tube structures were identified by an inverted light microscope. Tube length and branch point were calculated at 5 random fields using Image-Pro Plus 6.0 software (IPP, CA).

Luciferase activity assay
-------------------------

The 3′ untranslated region (UTR) of *PTEN* containing miR-21 binding sites was amplified through polymerase chain reaction (PCR) and was cloned into the downstream of the psiCHECK-2 luciferase vector (Promega, USA), which was named as wt 3′ UTR. The binding site was mutated using the GeneTailor Site-Directed Mutagenesis System (Invitrogen, USA) and the resultant mutant 3′ UTR was cloned into the same vector, which was named as mut 3′ UTR.

CMEC cells maintained in 48-well plates were co-transfected with different groups of vectors: 1 group was transfected with the combination of 200ng pGL3-control luciferase reporter, 10 ng pRL-TK vector, and miR-21 vector, while miR-21 vector was replaced by the negative control vector in the other group. Transfected cells were analyzed using the Dual-Luciferase Reporter Assay System (Promega) after 48 h.

RNA isolation and RT-PCR
------------------------

Total RNA from tissues or cells were extracted using TRIzol reagent (Invitrogen). ReverTra Ace qPCR RT Kit (Toyobo, Japan) was manipulated to reversely transcribe total RNA into cDNA and real-time PCR (RT-PCR) was performed using THUNDERBIRD SYBR^®^ qPCR Mix (Toyobo, Japan) using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Relevant primers were listed in [Table 1](#t1-medscimonit-22-3562){ref-type="table"}. Target gene expression levels were normalized to those of the control gene (GAPDH) and were calculated using the 2^−ΔΔCT^ method.

Western blot
------------

Tissues and cells were harvested and lysed by radio immunoprecipitation assay (RIPA) buffer. Total protein was separated and calculated as suggested by the Bradford method \[[@b24-medscimonit-22-3562]\]. Then, total protein was denatured in boiled water and transferred onto polyvinylidene fluoride (PVDF) membranes after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was completed. Membranes were blocked in Tris-Buffered Saline Tween (TBST) with 5% skim milk for 1 h and were then treated with primary antibodies against PTEN and VEGF (1:800 dilution, Zhongshan Biology Company, Beijing) at 4°C overnight. After membranes were washed, they were incubated with secondary antibodies (horseradish peroxidase-conjugated goat anti-goat, 1:2000 dilution, Zhongshan Biology Company, Beijing). Samples in which reduced GAPDH was set as the endogenous control were ultimately processed with enhanced chemiluminescence and were quantified using Lab Works4.5 software (Mitov Software).

Statistical analysis
--------------------

All statistical analyses results were obtained using SPSS 18.0 software (Chicago, Illinois, USA). Data are presented in the form of mean ± standard deviation (SD). The two-tailed *t* test or one-way analysis of variance (ANOVA) was used to analyze between-group comparisons and P\<0.05 was considered as the cut-off value of statistical significance.

Results
=======

Cell extraction and cell culture
--------------------------------

BMSCs and CMECs were isolated from cardiac tissues and then were identified with immunofluorescence staining of surface markers. Characteristic protein markers -- CD44 ([Figure 2A](#f2-medscimonit-22-3562){ref-type="fig"}), CD29 ([Figure 2B](#f2-medscimonit-22-3562){ref-type="fig"}), and CD106 ([Figure 2C](#f2-medscimonit-22-3562){ref-type="fig"}) -- were positively expressed in BMSCs. Endothelial-specific markers -- CD31 ([Figure 2D](#f2-medscimonit-22-3562){ref-type="fig"}), PDPN ([Figure 2E](#f2-medscimonit-22-3562){ref-type="fig"}), and Merge ([Figure 2F](#f2-medscimonit-22-3562){ref-type="fig"}) -- were positively expressed in CMECs.

MiR-21 regulated PTEN and VEGF expressions in BMSC cells
--------------------------------------------------------

As suggested by [Table 2](#t2-medscimonit-22-3562){ref-type="table"} and [Figure 3](#f3-medscimonit-22-3562){ref-type="fig"}, miR-21, PTEN, and VEGF expressions exhibited no significant differences between the control and NC group (all *P*\>0.05). Compared with the control and NC group, the miR-21 mimics group had significantly higher miR-21 and VEGF expressions and lower PTEN expressions, whereas the miR-21 inhibitors group had significantly lower miR-21 and VEGF expressions and higher PTEN expressions (all *P*\<0.05, [Table 2](#t2-medscimonit-22-3562){ref-type="table"}, [Figure 3](#f3-medscimonit-22-3562){ref-type="fig"}).

Results from echocardiographic measurement and endothelial injury markers
-------------------------------------------------------------------------

Rats in 5 groups (control, model, BMSC, miR-21 mimics, and miR-21 inhibitors) were associated with significantly lower LVEF and FS and remarkably higher LVVs and LVVd compared with the control group (all *P*\<0.05, [Table 3](#t3-medscimonit-22-3562){ref-type="table"}, [Figure 4](#f4-medscimonit-22-3562){ref-type="fig"}). In addition, the miR-21 mimics group had significantly higher LVEF and FS and lower LVVs and LVVd than the model group (all *P*\<0.05, [Table 3](#t3-medscimonit-22-3562){ref-type="table"}, [Figure 4](#f4-medscimonit-22-3562){ref-type="fig"}). The miR-21 inhibitors group also had significantly lower LVEF and FS as well as remarkably higher LVVs and LVVd than the BMSC group (all *P*\<0.05, [Table 3](#t3-medscimonit-22-3562){ref-type="table"}, [Figure 4](#f4-medscimonit-22-3562){ref-type="fig"}). The miR-21 inhibitors group exhibited significantly lower LVEF and FS in comparison to the miR-21 mimics group and the BMSC group exhibited significantly higher FS than the model group (all *P*\<0.05, [Table 3](#t3-medscimonit-22-3562){ref-type="table"}, [Figure 4](#f4-medscimonit-22-3562){ref-type="fig"}).

Endothelial injury markers, including cTnI, h-FABP and vWF, in the 5 groups were also evaluated and compared. Model rats had significantly higher cTnI, h-FABP, and vWF expressions, while treatment of miR-21 mimics further significantly up-regulated endothelial injury markers, especially h-FABP and vWF (all *P*\<0.05, [Table 3](#t3-medscimonit-22-3562){ref-type="table"}, [Figure 5](#f5-medscimonit-22-3562){ref-type="fig"}). The MiR-21 mimics group had remarkably lower expression of markers (cTnI, h-FABP, and vWF) compared with the model and miR-21 inhibitors group. Moreover, the MiR-21 mimics group exhibited significantly lower h-FABP and vWF expressions than the BMSC group (all *P*\<0.05, [Table 3](#t3-medscimonit-22-3562){ref-type="table"}, [Figure 5](#f5-medscimonit-22-3562){ref-type="fig"}). In addition, vWF was significantly down-regulated in the BMSC group compared to the model group (*P*\<0.05, [Table 3](#t3-medscimonit-22-3562){ref-type="table"}, [Figure 5](#f5-medscimonit-22-3562){ref-type="fig"}).

Masson's staining result
------------------------

By using Masson's trichrome staining, normal myocardium tissues were stained in red while fiberized tissues were stained in blue. Then, fibrosis area in the left ventricle wall was calculated ([Figure 6A--6E](#f6-medscimonit-22-3562){ref-type="fig"}). Compared with the control group, the fibrosis area was significantly increased in the model, BMSC, miR-21 mimics, and miR-21 inhibitors group (all *P*\<0.05, [Table 3](#t3-medscimonit-22-3562){ref-type="table"}, [Figure 6F](#f6-medscimonit-22-3562){ref-type="fig"}). Treatment of BMSC or miR-21 mimics remarkably restricted the fibrosis area compared with the model and miR-21 inhibitors group, while the miR-21 mimics group exhibited smaller fibrosis area compared with the BMSC group (all *P*\<0.05, [Table 3](#t3-medscimonit-22-3562){ref-type="table"}, [Figure 6F](#f6-medscimonit-22-3562){ref-type="fig"}).

MiR-21, PTEN, and VEGF expressions in cardiac tissues
-----------------------------------------------------

The model and miR-21 inhibitors group had significantly higher miR-21 and VEGF expressions and lower PTEN expressions than the control group (all *P*\<0.05, [Table 4](#t4-medscimonit-22-3562){ref-type="table"}, [Figure 7](#f7-medscimonit-22-3562){ref-type="fig"}). Treatment of miR-21 mimics significantly up-regulated miR-21 and VEGF expressions and down-regulated PTEN expressions compared with the control, model, BMSC, and miR-21 inhibitors group (all *P*\<0.05, [Table 4](#t4-medscimonit-22-3562){ref-type="table"}, [Figure 7](#f7-medscimonit-22-3562){ref-type="fig"}). miR-21 inhibitors exhibited remarkably lower miR-21 expressions compared with the BMSC group, while the BMSC group had significantly lower PTEN expression and higher VEGF expression than the model group (all *P*\<0.05, [Table 4](#t4-medscimonit-22-3562){ref-type="table"}, [Figure 7](#f7-medscimonit-22-3562){ref-type="fig"}).

miR-21 suppressed PTEN expression by binding with the 3′ UTR
------------------------------------------------------------

As suggested by results obtained using the miRanda software, 1 site in the 3′ UTR of PTEN was highly conserved to bind with miR-21 ([Figure 8A](#f8-medscimonit-22-3562){ref-type="fig"}). Luciferase activity assay confirmed a direct interaction between miR-21 and PTEN, with evidence that transfection of miR-21 could significantly restrict the relative luciferase activity in CMEC cells when miR-21 bound with the normal 3′ UTR of PTEN (*P*\<0.05, [Table 5](#t5-medscimonit-22-3562){ref-type="table"}, [Figure 8B](#f8-medscimonit-22-3562){ref-type="fig"}). Nonetheless, there appeared to be few differences in luciferase activities between the NC group and normal cells containing miR-21 in the control and PTEN mutation 3′ UTR group (*P*\>0.05, [Table 5](#t5-medscimonit-22-3562){ref-type="table"}, [Figure 8B](#f8-medscimonit-22-3562){ref-type="fig"}).

Effects of miR-21 and PTEN/VEGF on CMEC cell proliferation and apoptosis
------------------------------------------------------------------------

CMEC cell proliferation status was revealed by the MTT assay. Compared with the control, NC, miR-21 mimics + lenti-PTEN, and miR-21 mimics + VEGF siRNA group, the miR-21 mimics group had a significantly higher proliferation rate while the miR-21 inhibitors group had a significantly lower proliferation rate (all *P*\<0.05, [Table 6](#t6-medscimonit-22-3562){ref-type="table"}, [Figure 9A](#f9-medscimonit-22-3562){ref-type="fig"}).

Results from flow cytometry suggested that there was no obvious difference in cell apoptosis between the control, NC, miR-21 mimics, miR-21 mimics + lenti-PTEN, and miR-21 mimics + VEGF siRNA group (all *P*\>0.05, [Table 6](#t6-medscimonit-22-3562){ref-type="table"}, [Figure 9B](#f9-medscimonit-22-3562){ref-type="fig"}). Transfection of miR-21 inhibitors can remarkably elevate the apoptosis rate of CMEC cells compared with the control, NC, miR-21 mimics, miR-21 mimics + lenti-PTEN, and miR-21 mimics + VEGF siRNA group (all *P*\<0.05, [Table 6](#t6-medscimonit-22-3562){ref-type="table"}, [Figure 9B](#f9-medscimonit-22-3562){ref-type="fig"}).

Effects of miR-21 and PTEN/VEGF on CMEC cell angiogenesis
---------------------------------------------------------

As shown in [Table 6](#t6-medscimonit-22-3562){ref-type="table"} and [Figure 10](#f10-medscimonit-22-3562){ref-type="fig"}, no significant difference in tube length or tube branch point was found between the control and NC group (all *P*\>0.05). Compared with the control and NC group, the miR-21 mimics, miR-21 mimics + lenti PTEN, and miR-21 mimics + VEGF siRNA group showed obvious formation of dense cellular networks, including significantly larger tube length and more branch points, while the miR-21 inhibitors group had less obvious tube-like structures with smaller tube length and fewer branch points (all *P*\<0.05, [Table 6](#t6-medscimonit-22-3562){ref-type="table"}, [Figure 10](#f10-medscimonit-22-3562){ref-type="fig"}). Compared with the miR-21 mimics group, treatment of lenti PTEN or VEGF siRNA was able to down-regulate tube length and branch points, suggesting their negative effects on cell angiogenesis (all *P*\<0.05, [Table 6](#t6-medscimonit-22-3562){ref-type="table"}, [Figure 10](#f10-medscimonit-22-3562){ref-type="fig"}).

MiR-21, PTEN, and VEGF expressions in CMEC cells
------------------------------------------------

As indicated by [Table 7](#t7-medscimonit-22-3562){ref-type="table"} and [Figure 11](#f11-medscimonit-22-3562){ref-type="fig"}, miR-21, PTEN, and VEGF expressions had no significant differences between the control and NC group (all *P*\>0.05). Compared with of the control and NC group, the miR-21 mimics group had significantly higher miR-21 and VEGF expressions and lower PTEN expressions, whereas the miR-21 inhibitors group exhibited significantly lower miR-21 and VEGF expressions and higher PTEN expressions (all *P*\<0.05, [Table 7](#t7-medscimonit-22-3562){ref-type="table"}, [Figure 11](#f11-medscimonit-22-3562){ref-type="fig"}). Compared with the miR-21 mimics group, transfection of lenti-PTEN can significantly up-regulate PTEN expressions and down-regulate VEGF expressions, while transfection of VEGF siRNA is able to down-regulate VEGF expression (all *P*\<0.05, [Table 7](#t7-medscimonit-22-3562){ref-type="table"}, [Figure 11](#f11-medscimonit-22-3562){ref-type="fig"}).

Discussion
==========

As an emerging gene regulator, miRNAs are associated with cardiovascular diseases due to their participation in a wide range of processes; the importance of miRNAs has been discussed by prior studies \[[@b25-medscimonit-22-3562]\]. Several studies have reported a strong relationship between miRNAs and endothelial injury because endothelial activation is an initial step in the improvement of MI \[[@b26-medscimonit-22-3562]--[@b30-medscimonit-22-3562]\]. For example, endothelium-enriched miR-92a mediates athero-susceptible endothelial cells by regulating KLF2/4 expression at the mRNA and protein levels \[[@b29-medscimonit-22-3562],[@b31-medscimonit-22-3562]\]. Moreover, a recent study reported that Na~2~S exhibited a protective effect on cardiomyocytes \[[@b32-medscimonit-22-3562]\]. A study conducted by Olson et al. demonstrated that up-regulation of miR-21 mediated the cardio-protective effects induced by isoflurane in the ischemia-reperfusion (I/R) injury model \[[@b33-medscimonit-22-3562]\]. In our study, over-expression of miR-21 contributed to up-regulated CMEC proliferation and angiogenesis. Apart from that, over-expression of miR-21 is able to antagonize endothelial injury induced by the MI model. The above results suggest that miR-21 exerts protective roles in MI and may affect endothelial cell proliferation and angiogenesis.

VEGF is a strong angiogenesis inducer and has been suggested to be related to tumor angiogenesis in lung and prostate cancer \[[@b34-medscimonit-22-3562],[@b35-medscimonit-22-3562]\]. VEGF is an important regulator of neovascularization and it can effectively facilitate collateral circulation in ischemic myocardium \[[@b36-medscimonit-22-3562]\]. The main cause of myocardial necrosis is myocardial infarctions, which are in part caused by acute coronary artery blood supply interruption and severe myocardial tissue hypoxia. As shown in recent animal and clinical trials, VEGF expression is increased in myocardial infarction \[[@b37-medscimonit-22-3562]\]. The main mechanism of VEGF expression, which facilitates angiogenesis, may be that VEGF has a special effect on vascular endothelial cells and further influences endothelial cell proliferation, sprouting, migration, and luminal formation \[[@b38-medscimonit-22-3562]\]. In our study, up-regulation of VEGF expression induced by miR-21 mimics was related to less cardiac fibrosis, higher proliferation, and enhanced angiogenesis. Furthermore, interruption of VEGF expression with siRNA transfection is able to affect the protective effects of miR-21. Results from our study demonstrate that miR-21 regulates endothelial angiogenesis and exerts a protective effect through regulating VEGF expression. Interestingly, over-expression of miR-21 had no effects on cell apoptosis, while suppressing miR-21 can remarkably increase the apoptosis of CMECs. We suspect that VEGF is essential for the dynamics of CMECs, even if cell apoptosis is not affected by the over-expression of VEGF.

Some researchers reported that hypoxia-inducible factor-1 (HIF-1) plays a similar role to VEGF since the promoter region of VEGF gene contains the HIF-1 reactive element, which is active and directly induces VEGF expression under hypoxic conditions \[[@b39-medscimonit-22-3562]\]. MiR-21 regulates VEGF expression by elevating HIF-1 through ERK and AKT pathways in prostate cancer cells \[[@b35-medscimonit-22-3562]\]. However, PTEN, which is an antagonist of PI3K, was selected in our study as the mediator \[[@b40-medscimonit-22-3562]\]. Luciferase report assay has confirmed that miR-21 suppressed PTEN expression by binding with the 3′UTR of PTEN \[[@b41-medscimonit-22-3562]\]. Previous studies reported that the role of miR-21 was partly reflected by its ability to inhibit PTEN expression, while over-expression of PTEN interrupted tumor angiogenesis induced by miR-21 \[[@b42-medscimonit-22-3562], [@b43-medscimonit-22-3562]\]. In addition, Ma et al. reported that PTEN regulated VEGF-mediated signaling and modulated angiogenesis in human pancreatic cancer through the PI3K/Akt/VEGF pathway \[[@b16-medscimonit-22-3562]\]. Another recent study provided evidence that the PTEN/VEGF signaling pathway played an important role in argonaute2-induced angiogenesis in human hepatocellular carcinoma \[[@b44-medscimonit-22-3562]\]. As suggested by our study, PTEN expression is negatively associated with both miR-21 and VEGF expressions. Over-expression of PTEN can suppress the effects of miR-21 mimics on cell angiogenesis and down-regulate VEGF expression induced by miR-21. All of these conclusions provide new insights into the role of miR-21 in angiogenesis through the PTEN/VEGF signaling pathway and support our hypothesis that PTEN mediates the interaction between miR-21 and VEGF.

The present study has some limitations. For instance, the research approach in this study is not rigorous enough and we used a relatively small sample size, which may restrict the power of relevant statistical tests. Future studies should be designed and carried out to verify the representativeness and accuracy of our conclusions.

Conclusions
===========

In conclusion, miR-21 exhibited protective effects on cell proliferation and angiogenesis both *in vivo* and *in vitro*. Additionally, miR-21 regulated CMEC proliferation and angiogenesis through targeting and suppressing PTEN expression, which further elevated VEGF expression. PTEN is the downstream target of miR-21 and it down-regulates VEGF when angiogenesis is induced by miR-21.

**Source of support:** Departmental sources

![Animal model establishment and grouping. SD -- Sprague-Dawley; LAD -- left anterior descending; PBS -- phosphate buffer; BMSC -- bone marrow mesenchymal stem cells.](medscimonit-22-3562-g001){#f1-medscimonit-22-3562}

![Isolation and identification of BMSCs and CMECs. (**A--C**) Immunocytochemistry of BMSCs for a panel of surface markers, including CD44 (**A**), CD29 (**B**), and CD106 (**C**). (**D--F**) Immunocytochemistry of CMECs for a panel of endothelial-specific markers, including CD31 (**D**), PDPN (**E**) and Merge (**F**).](medscimonit-22-3562-g002){#f2-medscimonit-22-3562}

![MiR-21, PTEN, and VEGF expressions in BMSCs after transfection. (**A**) Semi-quantitative levels of miR-21in BMSCs among different groups (control, NC, miR-21 mimics, and miR-21 inhibitors). (**B**) Western blot analysis of PTEN and VEGF in BMSCs with GAPDH as internal control. (**C, D**) Quantitative protein level of PTEN (**C**) and VEGF (**D**) in BMSCs. Data are presented as mean ±SD for 3 independent experiments. \* *P*\<0.05 versus control group, ^\#^ *P*\<0.05 versus NC group, ^@^ *P*\<0.05 versus miR-21 mimics group.](medscimonit-22-3562-g003){#f3-medscimonit-22-3562}

![Echocardiographic measurements of LVEF (**A**), FS (**B**), LVVs (**C**), and LVVd (**D**). Data are presented as mean ±SD. LVEF -- left ventricular ejection fractions; FS -- fractional shortening; LVVs -- left ventricular end-systolic volume; LVVd -- left ventricular end-diastolic volume. \* *P*\<0.05 versus control group, ^\#^ *P*\<0.05 versus NC group, ^@^ *P*\<0.05 versus BMSC group, ^&^ *P*\<0.05 versus miR-21 mimics group.](medscimonit-22-3562-g004){#f4-medscimonit-22-3562}

![Quantitation of cTnI (**A**), h-FABP (**B**), vWF (**C**) in model rats. Data are presented as mean ±SD. cTnI -- cardiac troponin I; h-FABP -- heart-type fatty acid binding protein; vWF -- von Willebrand factor. \* *P*\<0.05 versus control group, ^\#^ *P*\<0.05 versus NC group, ^@^ *P*\<0.05 versus BMSC group, ^&^ *P*\<0.05 versus miR-21 mimics group.](medscimonit-22-3562-g005){#f5-medscimonit-22-3562}

![Results of Masson staining and fibrosis area. (**A--E**) Masson staining of atrial tissues in the control (**A**), model (**B**), BMSC (**C**), miR-21 mimics (**D**), and miR-21 inhibitors (**E**) group. F -- Fibrosis percentage (stained as blue) in left ventricle wall. Data are presented as mean ±SD. \* *P*\<0.05 versus control group, ^\#^ *P*\<0.05 versus NC group, ^@^ *P*\<0.05 versus BMSC group, ^&^ *P*\<0.05 versus miR-21 mimics group.](medscimonit-22-3562-g006){#f6-medscimonit-22-3562}

![MiR-21, PTEN, and VEGF expressions in model rats. (**A**) Quantitative levels of miR-21 in model rats among different groups (control, model, BMSC, miR-21 mimics, and miR-21 inhibitors). (**B**) Western blot analysis of PTEN and VEGF in cardiac tissues of rats with GAPDH as internal control. (**C, D**) Quantitative protein level of PTEN (**C**) and VEGF (**D**) in model rats. Data are presented as mean ±SD. \* *P*\<0.05 versus control group, ^\#^ *P*\<0.05 versus NC group, ^@^ *P*\<0.05 versus BMSC group, ^&^ *P*\<0.05 versus miR-21 mimics group.](medscimonit-22-3562-g007){#f7-medscimonit-22-3562}

![Binding site prediction and results of luciferase report between miR-21 and PTEN. (**A**) Putative targets predicted and binding site mutation. (**B**) Results of luciferase report. Data are presented as mean ±SD for 3 independent experiments. \* *P*\<0.05 versus control group.](medscimonit-22-3562-g008){#f8-medscimonit-22-3562}

![Quantitative data of proliferation rate (**A**) and apoptosis rate (**B**) in CMECs among different groups (control, NC, miR-21 mimics, miR-21 inhibitors, miR-21 mimics + lenti PTEN, and miR-21 mimics + VEGF siRNA). Data are presented as mean ±SD for 3 independent experiments. \* *P*\<0.05 versus control group, ^\#^ *P*\<0.05 versus NC group, ^@^ *P*\<0.05 versus miR-21 mimics group, ^&^ *P*\<0.05 versus miR-21 inhibitors group.](medscimonit-22-3562-g009){#f9-medscimonit-22-3562}

![Results of tube formation assay in CMEC cells. (**A--F**) Tube formation assay *in vitro* in the control (**A**), NC (**B**), miR-21 mimics (**C**), miR-21 inhibitors (**D**), miR-21 mimics + lenti PTEN (**E**), and miR-21 mimics + VEGF siRNA (**F**) group. (**G, H**) Quantitative data of tube length (**G**) and tube branch point (**H**) in CMECs. Data are presented as mean ±SD for 3 independent experiments. \* *P*\<0.05 versus control group, ^\#^ *P*\<0.05 versus NC group, ^@^ *P*\<0.05 versus miR-21 mimics group, ^&^ *P*\<0.05 versus miR-21 inhibitors group.](medscimonit-22-3562-g010){#f10-medscimonit-22-3562}

![MiR-21, PTEN, and VEGF expressions in CMECs after transfection. (**A**) Quantitative levels of miR-21in CMECs among different groups (control, NC, miR-21 mimics, miR-21 inhibitors, miR-21 mimics + lenti PTEN, and miR-21 mimics + VEGF siRNA). (**B**) Western blot analysis of PTEN and VEGF in CMECs with GAPDH as internal control. (**C, D**) Quantitative protein level of PTEN (**C**) and VEGF (**D**) CMECs. Data are presented as mean ±SD for 3 independent experiments. ^\*^ *P*\<0.05 versus control group, ^\#^ *P*\<0.05 versus NC group, ^@^ *P*\<0.05 versus miR-21 mimics group, ^&^ *P*\<0.05 versus miR-21 inhibitors group, ^\^^ *P*\<0.05 versus miR-21 mimics + lenti PTEN group.](medscimonit-22-3562-g011){#f11-medscimonit-22-3562}

###### 

Primer sequences of GAPDH and miR-21 for implemention of RT-PCR.

  Gene                                      Primer sequence
  ----------- ----------------------------- -----------------------------
  GAPDH       Sense                         5′-TGGTATCGTGGAAGGACTCAT-3′
                                            
  Antisense   5′-GTGGGTGTCGCTGTTGAAGTC-3′   
                                            
  miR-21      Sense                         5′-GCGCGTCGTGAAGCGTTC-3′
  Antisense   5′-GTGCAGGGTCCGAGGT-3′        

GAPDH -- glyceraldehyde phosphate dehydrogenase glyceraldehyde phosphate dehydrogenase; RT-PCR -- real time-polymerase chain reaction.

###### 

Expressions of miR-21, PTEN and VEGF in BMSC cells.

  Group    Control     NC          MiR-21 mimics                                                                                                       MiR-21 inhibitors
  -------- ----------- ----------- ------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miR-21   1.00±0.07   0.97±0.10   4.44±.67[\*](#tfn3-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn4-medscimonit-22-3562){ref-type="table-fn"}    0.24±0.05[\*](#tfn3-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn4-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn5-medscimonit-22-3562){ref-type="table-fn"}
  PTEN     1.00±0.07   0.99±0.09   0.44±0.11[\*](#tfn3-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn4-medscimonit-22-3562){ref-type="table-fn"}   1.92±0.22[\*](#tfn3-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn4-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn5-medscimonit-22-3562){ref-type="table-fn"}
  VEGF     1.00±0.08   1.02±0.08   1.98±0.31[\*](#tfn3-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn4-medscimonit-22-3562){ref-type="table-fn"}   0.41±0.10[\*](#tfn3-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn4-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn5-medscimonit-22-3562){ref-type="table-fn"}

NC -- negative control.

*P*\<0.05 versus control group;

*P*\<0.05 versus NC group;

*P*\<0.05 versus miR-21 mimics group.

###### 

Results of echocardiographic measurement, endothelial injury marker tests and masson staining.

  Group           Control      Model                                                            BMSC                                                                                                                 MiR-21 mimics                                                                                                                                                           MiR-21 inhibitors
  --------------- ------------ ---------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  LVEF, %         67.8±6.2     42.9±7.8[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}     47.5±6.4[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}                                                         52.3±5.2[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}                                                        39.3±4.7[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn9-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn10-medscimonit-22-3562){ref-type="table-fn"}
  FS, %           36.2±2.3     22.2±3.9[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}     26.9±4.8[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}     29.2±5.2[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}                                                        20.2±4.2[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn9-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn10-medscimonit-22-3562){ref-type="table-fn"}
  LVVs, ml        2.8±0.3      3.8±0.6[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}      3.5±0.5[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}                                                          3.3±0.5[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}                                                         3.8±0.5[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn10-medscimonit-22-3562){ref-type="table-fn"}
  LVVd, ml        5.2±0.7      6.3±0.4[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}      6.0±0.4[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}                                                          5.8±0.4[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}                                                         6.4±0.5[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn10-medscimonit-22-3562){ref-type="table-fn"}
  cTnI, pg/ml     11.68±1.43   16.37±2.13[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}   15.12±2.08[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}                                                       13.55±2.26[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}                                                                                                          17.86±2.37[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn9-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn10-medscimonit-22-3562){ref-type="table-fn"}
  h-FABP, ng/ml   10.35±1.79   18.78±2.74[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}   17.12±2.69[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}                                                       14.57±2.31[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn9-medscimonit-22-3562){ref-type="table-fn"}   23.32±3.15[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn9-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn10-medscimonit-22-3562){ref-type="table-fn"}
  vWF, ng/ml      4.79±0.87    8.15±1.15[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}    7.17±1.14[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}    5.82±0.95[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn9-medscimonit-22-3562){ref-type="table-fn"}    9.28±1.26[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn9-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn10-medscimonit-22-3562){ref-type="table-fn"}
  Fibrosis, %LV   0±0          47.71±3.18[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}   35.04±4.38[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}   20.36±2.39[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn8-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn9-medscimonit-22-3562){ref-type="table-fn"}   48.70±3.19[\*](#tfn7-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn9-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn10-medscimonit-22-3562){ref-type="table-fn"}

LVEF -- left ventricular ejection fractions; FS -- fractional shortening; LVVs -- left ventricular end-systolic volume; LVVd -- left ventricular end-diastolic volume; cTnI -- cardiac troponin I; h-FABP -- heart-type fatty acid binding protein; vWF -- von Willebrand factor.

*P*\<0.05 versus control group;

*P*\<0.05 versus NC group;

*P*\<0.05 versus BMSC group,

*P*\<0.05 versus miR-21 mimics group.

###### 

Expression level of miR-21, PTEN and VEGF in cardiac tissue.

  Group    Control     Model                                                            BMSC                                                                                                                  MiR-21 mimics                                                                                                                                                             MiR-21 inhibitors
  -------- ----------- ---------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miR-21   1.00±0.07   1.78±0.11[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}   1.82±0.13[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}                                                        2.85±0.32[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn12-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn13-medscimonit-22-3562){ref-type="table-fn"}   1.69±0.12[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn13-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn14-medscimonit-22-3562){ref-type="table-fn"}
  PTEN     1.00±0.08   0.82±0.07[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}   0.76±0.05[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn12-medscimonit-22-3562){ref-type="table-fn"}   0.56±0.05[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn12-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn13-medscimonit-22-3562){ref-type="table-fn"}   0.80±0.07[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn14-medscimonit-22-3562){ref-type="table-fn"}
  VEGF     1.00±0.08   1.32±0.10[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}   1.48±0.14[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn12-medscimonit-22-3562){ref-type="table-fn"}   1.92±0.19[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn12-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn13-medscimonit-22-3562){ref-type="table-fn"}   1.41±0.13[\*](#tfn11-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn14-medscimonit-22-3562){ref-type="table-fn"}

*P*\<0.05 versus control group;

*P*\<0.05 versus NC group;

*P*\<0.05 versus BMSC group;

*P*\<0.05 versus miR-21 mimics group.

###### 

Relative luciferase activity in wt VEGF-A, Mut VEGF-A and vector groups.

  Relative luciferase activity   Wt                                                               Mut         Vector
  ------------------------------ ---------------------------------------------------------------- ----------- -----------
  NC                             1.00±0.07                                                        1.00±0.08   1.00±0.07
  Transfection group             0.42±0.06[\*](#tfn16-medscimonit-22-3562){ref-type="table-fn"}   1.08±0.07   0.96±0.06

Wt -- wild type; Mut -- mutation; NC -- negative control.

*P*\<0.05 versus NC group.

###### 

Effects of miR-21, lenti PTEN and VEGF siRNA on proliferation, apoptosis and angiogenesis of CMEC cells.

  Group             Control      NC           MiR-21 mimics                                                                                                          MiR-21 inhibitors                                                                                                                                                          MiR-21 mimics + lenti PTEN                                                                                                                                                                                                     MiR-21 mimics + VEGF siRNA
  ----------------- ------------ ------------ ---------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Proliferation     1.00±0.06    0.98±0.03    1.21±0.08[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}    0.72±0.06[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3562){ref-type="table-fn"}    1.08±0.07[@](#tfn19-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn20-medscimonit-22-3562){ref-type="table-fn"}                                                                                                              1.07±0.07[@](#tfn19-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn20-medscimonit-22-3562){ref-type="table-fn"}
  Apoptosis,%       9.95±1.50    9.85±0.75    10.04±1.13                                                                                                             32.99±1.51[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3562){ref-type="table-fn"}   9.87±1.48[&](#tfn20-medscimonit-22-3562){ref-type="table-fn"}                                                                                                                                                                  10.02±1.32[&](#tfn20-medscimonit-22-3562){ref-type="table-fn"}
  Tube length, mm   13.17±0.45   13.82±0.60   22.60±0.90[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}   11.77±0.45[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3562){ref-type="table-fn"}   17.24±0.53[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn20-medscimonit-22-3562){ref-type="table-fn"}   16.33±0.47[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn20-medscimonit-22-3562){ref-type="table-fn"}
  Branch point      35.81±3.26   36.44±4.07   54.94±5.29[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}   29.71±4.48[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3562){ref-type="table-fn"}   46.78±3.74[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn20-medscimonit-22-3562){ref-type="table-fn"}   43.25±3.64[\*](#tfn17-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn18-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn19-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn20-medscimonit-22-3562){ref-type="table-fn"}

*P*\<0.05 versus control group;

*P*\<0.05 versus NC group;

*P*\<0.05 versus miR-21 mimics group;

*P*\<0.05 versus miR-21 inhibitors group.

###### 

Expression level of miR-21, PTEN and VEGF in CMEC cells.

  Group    Control     NC          MiR-21 mimics                                                                                                         MiR-21 inhibitors                                                                                                                                                         MiR-21 mimics + lenti PTEN                                                                                                                                                                                                    MiR-21 mimics + VEGF siRNA
  -------- ----------- ----------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miR-21   1.00±0.06   1.02±0.10   3.98±0.59[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}   0.25±0.05[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn23-medscimonit-22-3562){ref-type="table-fn"}   3.88±0.57[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn24-medscimonit-22-3562){ref-type="table-fn"}                                                       3.93±0.62[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn24-medscimonit-22-3562){ref-type="table-fn"}
  PTEN     1.00±0.06   1.03±0.09   0.39±0.10[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}   1.96±0.24[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn23-medscimonit-22-3562){ref-type="table-fn"}   0.79±0.07[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn23-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn24-medscimonit-22-3562){ref-type="table-fn"}   0.42±0.11[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn24-medscimonit-22-3562){ref-type="table-fn"}[\^](#tfn25-medscimonit-22-3562){ref-type="table-fn"}
  VEGF     1.00±0.07   0.98±0.08   2.12±0.33[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}   0.38±0.09[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn23-medscimonit-22-3562){ref-type="table-fn"}   1.53±0.14[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn23-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn24-medscimonit-22-3562){ref-type="table-fn"}   1.42±0.17[\*](#tfn21-medscimonit-22-3562){ref-type="table-fn"}[\#](#tfn22-medscimonit-22-3562){ref-type="table-fn"}[@](#tfn23-medscimonit-22-3562){ref-type="table-fn"}[&](#tfn24-medscimonit-22-3562){ref-type="table-fn"}

*P*\<0.05 versus control group;

*P*\<0.05 versus NC group;

*P*\<0.05 versus miR-21 mimics group;

*P*\<0.05 versus miR-21 inhibitors group;

*P*\<0.05 versus miR-21 mimics + lenti PTEN group.
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